Industry Sponsorship and Disease Site Focus in Therapeutic Radiopharmaceutical Clinical Trials Over the Past Decade
RPT trials demonstrated consistent growth over the past decade, largely driven by robust industry support, and have predominantly focused on targeted <sup>177</sup>Lu-based RPTs for the treatment of prostate adenocarcinoma and gastrointestinal neuroendocrine tumors.
Authors
- Neil K. Taunk (ORCID: https://orcid.org/0000-0002-1349-9774)
- Dustin Boothe
- Skyler B. Johnson (ORCID: https://orcid.org/0000-0002-8881-7706)
- Ravi B. Patel (ORCID: https://orcid.org/0000-0002-8328-746X)
- Freddy E. Escorcia (ORCID: https://orcid.org/0000-0002-0727-3242)
- Nichole M. Maughan (ORCID: https://orcid.org/0000-0001-7230-9793)
- Brandon M. Barney
- J. M. Howell
- Jacob Wilkes
Institutions
- Intermountain Healthcare (US)
- University of Pittsburgh (US)
- Huntsman Cancer Institute (US)
- Intermountain Medical Center (US)
- National Cancer Institute (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- International Journal of Radiation Oncology*Biology*Physics
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1016/j.ijrobp.2025.09.028
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Society of Nuclear Medicine and Molecular Imaging
- Varian Medical Systems
- Society for Immunotherapy of Cancer
- National Comprehensive Cancer Network
- Bayer HealthCare
- National Institutes of Health
- National Cancer Institute